Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 8/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.81 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.81 |
| ▸ | PGR | P06401 | 2/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.81 |
| ▸ | HTR2B | P41595 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.60 |
| ▸ | BLM | P54132 | 4/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyltestosterone SCHEMBL18657 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A | |
| Methyltestosterone SCHEMBL6472960 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A | |
| Methyltestosterone SCHEMBL13575766 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A | |
| Methyltestosterone SCHEMBL18891626 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A | |
| Methyltestosterone SCHEMBL5021655 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A | |
| Methyltestosterone SCHEMBL13965283 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A | |
| Methyltestosterone SCHEMBL4442874 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A | |
| Methyltestosterone SCHEMBL13768123 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A | |
| Methyltestosterone SCHEMBL6152059 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A | |
| Methyltestosterone SCHEMBL29416593 | 0.90 | SHBG (1.00) | SHBGALDH1A1NR3C1PGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177759-A1 | COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA-GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2018-06-28 | — | — | US | claimed |
| EP-3285753-A1 | COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA -GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER | CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) | 2018-02-28 | — | — | EP | claimed |
| WO-2016170102-A1 | COMBINATION OF AN ANTIANDROGEN WITH A VITAMIN K ANTAGONIST OR WITH A GAMMA -GLUTAMYL CARBOXYLASE INHIBITOR FOR THE THERAPY OF ANDROGEN RECEPTOR POSITIVE CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2016-10-27 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20110003748-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2011-01-06 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE | 2009-08-27 | — | — | US | claimed |
| EP-2077844-A2 | METHOD OF TREQATMENT AND COMPOSITIONS OF D-CHRIRO INOSITOL AND PHOSPHATES THEREOF | Jennings-Spring, Barbara L. (US) | 2009-07-15 | — | — | EP | claimed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | JENNINGS-SPRING BARBARA L | 2008-06-12 | — | — | US | claimed |
| WO-2008066634-A2 | METHOD OF TREQATMENT AND COMPOSITIONS OF D-CHRIRO INOSITOL AND PHOSPHATES THEREOF | JENNINGS-SPRING BARBARA L (US) | 2008-06-05 | — | — | WO | claimed |
| US-20080103116-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | JENNINGS-SPRING BARBARA L | 2008-05-01 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003748-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | PPIP5K2, SHBG, CYP24A1 | SHBG 2/4885ALDH1A1 2087/4885NR3C1 751/4885 |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SHBG 2047/4885ALDH1A1 121/4885NR3C1 1994/4885 |
| US-20080138379-A1 | Preventing birth defects; administering formulation to women from preconception through first trimester of pregnancy | PGF, ERH, BRCA1 | SHBG 444/4885ALDH1A1 2034/4885NR3C1 780/4885 |
| US-20080103116-A1 | Method of treatment and compositions of D-chiro inositol and phosphates thereof | PPIP5K2, SHBG, CYP24A1 | SHBG 2/4885ALDH1A1 2087/4885NR3C1 751/4885 |
| US-20090214474-A1 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | SHH, ERH, CDK5 | SHBG 2076/4885ALDH1A1 1846/4885NR3C1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.